List view / Grid view




Boom times for pharma M&A

18 February 2021 | By

Global mergers and acquisitions (M&A) activity last year was expected to decline from 2019 levels, mainly due to the COVID-19 pandemic and resulting uncertainty around the global economy, trade tensions between the US and China, and the presidential election in the US. However, James Baillieu from Bird & Bird reveals…


NICE recommends Apremilast for treating psoriatic arthritis

11 October 2016 | By Niamh Louise Marriott, Digital Content Producer

The National Institute for Health and Care Excellence (NICE) has released draft guidance recommending Apremilast for the treatment of psoriatic arthritis in adults. This appraisal was a rapid review of the NICE technology appraisal guidance published in December 2015. It focused on cost-effectiveness analyses using a patient access scheme agreement, which provides apremilast at…


EC approves Revlimid for mantle cell lymphoma

15 July 2016 | By Victoria White, Digital Content Producer

Celgene’s Revlimid (lenalidomide) has been approved by the EC for the treatment of adult patients with relapsed or refractory mantle cell lymphoma...